Hybio Pharmaceutical Past Earnings Performance
Past criteria checks 0/6
Hybio Pharmaceutical has been growing earnings at an average annual rate of 19.6%, while the Pharmaceuticals industry saw earnings growing at 9% annually. Revenues have been declining at an average rate of 9.9% per year.
Key information
19.6%
Earnings growth rate
18.5%
EPS growth rate
| Pharmaceuticals Industry Growth | 10.9% |
| Revenue growth rate | -9.9% |
| Return on equity | -63.0% |
| Net Margin | -135.5% |
| Last Earnings Update | 30 Jun 2024 |
Recent past performance updates
Recent updates
Revenue & Expenses Breakdown
How Hybio Pharmaceutical makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 30 Jun 24 | 362 | -490 | 289 | 115 |
| 31 Mar 24 | 405 | -547 | 342 | 136 |
| 31 Dec 23 | 431 | -514 | 371 | 161 |
| 30 Sep 23 | 575 | -404 | 452 | 170 |
| 30 Jun 23 | 673 | -306 | 506 | 181 |
| 31 Mar 23 | 713 | -294 | 531 | 177 |
| 01 Jan 23 | 704 | -371 | 520 | 155 |
| 30 Sep 22 | 759 | 2 | 566 | 135 |
| 30 Jun 22 | 726 | -41 | 569 | 121 |
| 31 Mar 22 | 725 | -50 | 621 | 93 |
| 01 Jan 22 | 736 | 31 | 616 | 102 |
| 30 Sep 21 | 542 | -783 | 928 | 156 |
| 30 Jun 21 | 648 | -683 | 958 | 153 |
| 31 Mar 21 | 708 | -608 | 923 | 158 |
| 31 Dec 20 | 722 | -609 | 962 | 140 |
| 30 Sep 20 | 745 | -749 | 744 | 166 |
| 30 Jun 20 | 604 | -914 | 792 | 162 |
| 31 Mar 20 | 613 | -914 | 802 | 168 |
| 31 Dec 19 | 614 | -885 | 791 | 175 |
| 30 Sep 19 | 916 | -714 | 852 | 97 |
| 30 Jun 19 | 1,068 | -474 | 742 | 92 |
| 31 Mar 19 | 1,189 | -387 | 764 | 92 |
| 01 Jan 19 | 1,264 | -341 | 790 | 91 |
| 30 Sep 18 | 1,437 | 389 | 727 | 94 |
| 30 Jun 18 | 1,414 | 379 | 657 | 130 |
| 31 Mar 18 | 1,309 | 350 | 618 | 106 |
| 31 Dec 17 | 1,246 | 330 | 558 | 89 |
| 30 Sep 17 | 955 | 296 | 353 | 51 |
| 30 Jun 17 | 990 | 342 | 387 | 0 |
| 31 Mar 17 | 894 | 312 | 325 | 0 |
| 31 Dec 16 | 855 | 292 | 321 | 0 |
| 30 Sep 16 | 926 | 361 | 323 | 0 |
| 30 Jun 16 | 846 | 326 | 293 | 0 |
| 31 Mar 16 | 813 | 326 | 268 | 0 |
| 31 Dec 15 | 768 | 305 | 259 | 0 |
| 30 Sep 15 | 592 | 241 | 198 | 0 |
| 30 Jun 15 | 527 | 212 | 184 | 0 |
| 31 Mar 15 | 475 | 188 | 168 | 0 |
| 31 Dec 14 | 419 | 172 | 158 | 0 |
| 30 Sep 14 | 400 | 166 | 152 | 0 |
| 30 Jun 14 | 342 | 138 | 144 | 0 |
| 31 Mar 14 | 321 | 133 | 134 | 0 |
| 31 Dec 13 | 301 | 130 | 120 | 0 |
| 30 Sep 13 | 262 | 97 | 112 | 0 |
Quality Earnings: 300199 is currently unprofitable.
Growing Profit Margin: 300199 is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: 300199 is unprofitable, but has reduced losses over the past 5 years at a rate of 19.6% per year.
Accelerating Growth: Unable to compare 300199's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: 300199 is unprofitable, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (-0.6%).
Return on Equity
High ROE: 300199 has a negative Return on Equity (-63.01%), as it is currently unprofitable.